Literature DB >> 7726211

Study of the possible association of HLA class II, CD4, and CD3 polymorphisms with schizophrenia.

M G Zamani1, M De Hert, M Spaepen, M Hermans, P Marynen, J J Cassiman, J Peuskens.   

Abstract

In the present study the HLA-DRB and DPB1 alleles as well as CD4 and CD3 polymorphisms were tested in 100 Belgian schizophrenic patients and 204 controls. Our results indicate a significant negative association of the DPB1 0101 allele with schizophrenia (relative risk [RR] = 0.27). Furthermore a significant positive and negative association could be noticed for the CD4*A4 allele and CD4*A7/A8 genotype, respectively (RR 1.79 and 0.47, respectively). These findings suggest that some contribution of HLA class II and CD4 genes to an autoimmune-like pathogenesis in schizophrenia might exist.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7726211     DOI: 10.1002/ajmg.1320540417

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  3 in total

1.  Association of CD4 enhancer gene polymorphisms with rheumatoid arthritis in Egyptian female patients.

Authors:  Yousri M Hussein; Shereen A El Tarhouny; Randa H Mohamed; Amal S El-Shal; Amany M Abul-Saoud; Manal Abdo
Journal:  Rheumatol Int       Date:  2011-05-28       Impact factor: 2.631

Review 2.  Molecular genetics of schizophrenia: past, present and future.

Authors:  Suman Prasad; Prachi Semwal; Smita Deshpande; Triptish Bhatia; V L Nimgaonkar; B K Thelma
Journal:  J Biosci       Date:  2002-02       Impact factor: 1.826

3.  Comprehensive exploration of the effects of miRNA SNPs on monocyte gene expression.

Authors:  Nicolas Greliche; Tanja Zeller; Philipp S Wild; Maxime Rotival; Arne Schillert; Andreas Ziegler; Panos Deloukas; Jeanette Erdmann; Christian Hengstenberg; Willem H Ouwehand; Nilesh J Samani; Heribert Schunkert; Thomas Munzel; Karl J Lackner; François Cambien; Alison H Goodall; Laurence Tiret; Stefan Blankenberg; David-Alexandre Trégouët
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.